OS Therapies Says FDA Voucher Shelving Has No Impact
The company says the FDA's shelving of its Commissioner's National Priority Voucher program does not affect its pediatric rare disease voucher eligibility.
Updated on Nov. 13, 2026 in Health

OS Therapies Inc. announced that the FDA's shelving of the Commissioner's National Priority Voucher program has no impact on the company. The company also reported receiving approximately $900,000 in UK tax credits from HM Revenue and Customs.
Why it matters
The company says the shelving does not affect the FDA rare pediatric disease priority review voucher program, which remains statutorily authorized through September 30, 2029. Maryland-based OS Therapies' lead candidate, OST-HER2, may qualify for such a voucher if approved in time.
The company reports approximately $900,000 in its latest UK tax credit from HM Revenue and Customs and cites a rare pediatric disease PRV program authorized through September 30, 2029. Whether OST-HER2 will win FDA approval before that deadline is not yet known.
The players
OS Therapies Inc.
OS Therapies is a company developing immunotherapies, including OST-HER2 for osteosarcoma, and is headquartered in Grasonville, Maryland.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency that regulates drugs and biologics and administers the rare pediatric disease priority review voucher program.
The details
OS Therapies said the FDA shelved its Commissioner's National Priority Voucher program but that the separate rare pediatric disease PRV program is unaffected. The company holds Orphan Drug, Fast Track and Rare Pediatric Disease designations for OST-HER2, an immunotherapy using Listeria bacteria to target the HER2 protein.
Timeline
September 30, 2029: rare pediatric disease PRV program authorization expires and deadline for OST-HER2 voucher eligibility
Q4 2026: planned Biologics License Application submission to the FDA and conditional marketing authorization requests to the MHRA and EMA
Regulatory Pathway
The company's voucher eligibility depends on the FDA rare pediatric disease PRV program, which is statutorily authorized through September 30, 2029, and the FDA's separate Commissioner's National Priority Voucher program has now been shelved. OST-HER2's path to a voucher therefore runs through the older statutory program rather than the discontinued one.
If approved, OST-HER2 would be a new immunotherapy option for osteosarcoma patients, a rare bone cancer. Approval timelines and the voucher eligibility deadline will determine how quickly the treatment could reach patients.
The takeaway
Regulatory voucher programs can shift the economics and timing of rare disease drug development, so policy changes like the shelving of one FDA program are worth tracking even when a company says they have no direct effect.
What happens next
OS Therapies plans to submit a Biologics License Application to the FDA for OST-HER2 in Q4 2026, with conditional marketing authorization requests to the MHRA and EMA in the same quarter.
Further reading
Explore more Cancer coverage for context on drug development and regulatory pathways.
Source note: This article includes information reported by Owen Sound Sun Times.






